September 24, 2020

The Niche

Knoepfler lab stem cell blog

Geron

1 min read

I’ve added a fun and helpful new feature on the right side bar of the blog in the form of a stem cell biotech stock ticker. The ticker is for some of the most widely held stem and cellular medicine companies. A sample screen shot is shown in this post. Quite a few stem cell-related stocks could not be added to this ticker for various reasons including ACTC, Mesoblast, CUR, and others. Yahoo has limits on which stocks can be included based on company …Read More

3 min read

Who do you turn to when you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future? There are only a handful of people and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy phone interview and conversation that I had with West. Today in Part 2 we are focused on clinical development of human ES cells and what happened with …Read More

2 min read

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock symbol ACTC) in the early days. He contributed to the team that made human embryonic stem cells (hESC) a reality too. West and I talked at length about the …Read More

1 min read

Today the Supreme Court announced it would not hear the Sherley v Sebelius case, ending the court battle that has left embryonic stem cell research (ESCR) in what I’ve called a “big chill”. This is great news. It is all over the mainstream media. Even the rampant anti-science, pro-lifers have declared defeat. I’m not going to link to them, take my word for it they are depressed big time. Don’t count them out yet though as they are smart and powerful as well as …Read More